Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05873595 · ClinicalTrials.gov registry record
Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease
A clinical trial, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Terminated
- Registry status
- 29
- Enrollment target
NCT05873595: Clinical Trial study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT05873595 is a clinical trial that was terminated before completion, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05873595 was terminated before completion, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- TERMINATED
- Registry status
- 29 participants
- Enrollment target
Study Summary
This is an observational study, meaning participants will not receive any investigational treatment as part of this study. Researchers will collect real-world data (RWD) to gain a more in-depth knowledge of the treatment of Peyronie's Disease (PD) to evaluate the management of PD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-06-20 |
| Est. Completion | 2024-02-26 |
Why NCT05873595 stopped before completion
NCT05873595 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 29 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05873595 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05873595 about?
NCT05873595 is a clinical study titled "Real-World Data Study to Understand Effectiveness of Treatments in Peyronie's Disease". This is an observational study, meaning participants will not receive any investigational treatment as part of this study. Researchers will collect real-world data (RWD) to gain a more in-depth knowledge of the treatment of Peyronie's Disease (PD) to evaluate the management of PD.
What is the current status of trial NCT05873595?
This trial is currently terminated. The enrollment target is 29 participants. The study started on 2023-06-20. Estimated completion is 2024-02-26.
Who is sponsoring clinical trial NCT05873595?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI